DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET.
A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay on that site following the event.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and X. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Contact:
Dave Crawford
919-474-6787
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.57 |
| Daily Change: | 0.06 0.92 |
| Daily Volume: | 225,348 |
| Market Cap: | US$439.470M |
September 03, 2025 August 06, 2025 July 30, 2025 May 06, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
